See more : Teligent, Inc. (TLGT) Income Statement Analysis – Financial Results
Complete financial analysis of CV Sciences, Inc. (CVSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CV Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Qt Group Oyj (QTGPF) Income Statement Analysis – Financial Results
- LOTTE Himart Co.,Ltd. (071840.KS) Income Statement Analysis – Financial Results
- BankInvest – Emerging Markets Obligationer Lokalvaluta (BAIEMOLVA.CO) Income Statement Analysis – Financial Results
- Pfizer Inc. (PFE.BA) Income Statement Analysis – Financial Results
- ObsEva SA (OBSN.SW) Income Statement Analysis – Financial Results
CV Sciences, Inc. (CVSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cvsciences.com
About CV Sciences, Inc.
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00M | 16.21M | 20.05M | 24.43M | 53.70M | 48.24M | 20.68M | 11.06M | 11.53M | 10.19M | 2.15M | 0.00 | 0.00 |
| Cost of Revenue | 8.92M | 10.66M | 11.43M | 13.42M | 18.61M | 14.37M | 6.19M | 4.06M | 4.42M | 4.39M | 880.47K | 0.00 | 0.00 |
| Gross Profit | 7.09M | 5.55M | 8.62M | 11.01M | 35.09M | 33.88M | 14.49M | 7.00M | 7.11M | 5.80M | 1.27M | 0.00 | 0.00 |
| Gross Profit Ratio | 44.27% | 34.25% | 42.98% | 45.07% | 65.35% | 70.22% | 70.06% | 63.27% | 61.65% | 56.95% | 59.13% | 0.00% | 0.00% |
| Research & Development | 151.00K | 307.00K | 1.19M | 2.94M | 5.88M | 1.89M | 724.33K | 1.16M | 1.32M | 999.28K | 524.48K | 0.00 | 0.00 |
| General & Administrative | 6.55M | 3.89M | 13.93M | 19.36M | 34.39M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 0.00 | 88.09K |
| Selling & Marketing | 2.94M | 8.20M | 11.95M | 11.30M | 12.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.49M | 12.09M | 25.88M | 30.66M | 46.45M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 43.02K | 88.09K |
| Other Expenses | -5.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27K | -8.55K | -73.21K | -34.82K | 0.00 | 43.02K | 0.00 |
| Operating Expenses | 3.73M | 12.40M | 27.06M | 33.60M | 52.33M | 23.63M | 16.98M | 13.91M | 19.07M | 14.36M | 2.89M | 43.02K | 88.09K |
| Cost & Expenses | 12.64M | 23.05M | 38.49M | 47.02M | 70.94M | 38.00M | 23.17M | 17.97M | 23.50M | 18.74M | 3.77M | 43.02K | 88.09K |
| Interest Income | 0.00 | 1.54M | 140.00K | 9.00K | 15.00K | 0.00 | 2.00 | 27.66K | 18.29K | 30.70K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.54M | 140.00K | 9.00K | 0.00 | 153.00K | 506.38K | 1.09M | 968.62K | 615.34K | 372.11K | 2.59K | 2.09K |
| Depreciation & Amortization | 235.00K | 1.06M | 1.50M | 1.47M | 1.53M | 519.00K | 182.00K | 1.05M | 1.01M | 933.60K | 767.25K | 43.02K | 0.00 |
| EBITDA | 3.85M | -5.66M | -14.00M | -21.72M | -15.69M | 10.77M | -4.69M | -12.00M | -10.25M | 236.99K | -1.16M | -2.59K | -88.09K |
| EBITDA Ratio | 24.03% | -36.13% | -86.26% | -88.91% | -30.77% | 22.32% | -11.21% | -52.80% | -95.49% | -75.19% | -39.46% | 0.00% | 0.00% |
| Operating Income | 3.36M | -6.85M | -18.45M | -22.59M | -17.24M | 10.25M | -4.86M | -13.07M | -11.21M | -8.55M | -1.62M | -43.02K | -88.09K |
| Operating Income Ratio | 20.99% | -42.25% | -92.01% | -92.48% | -32.11% | 21.24% | -23.50% | -118.20% | -97.23% | -83.93% | -75.08% | 0.00% | 0.00% |
| Total Other Income/Expenses | -264.00K | -1.41M | 2.81M | -9.00K | 15.00K | -153.00K | -519.00K | -1.07M | -1.02M | 7.24M | -682.86K | -2.59K | -2.09K |
| Income Before Tax | 3.10M | -8.26M | -15.64M | -22.60M | -17.23M | 10.09M | -5.38M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Income Before Tax Ratio | 19.35% | -50.98% | -78.02% | -92.52% | -32.08% | 20.92% | -26.01% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| Income Tax Expense | -6.00K | -47.00K | -87.00K | -317.00K | -615.00K | 93.00K | -481.50K | 1.08M | 895.40K | 541.98K | 372.11K | -43.02K | 0.00 |
| Net Income | 3.10M | -8.21M | -15.55M | -22.28M | -16.61M | 10.00M | -4.90M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Net Income Ratio | 19.38% | -50.69% | -77.58% | -91.22% | -30.93% | 20.73% | -23.68% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| EPS | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 153.95M | 138.03M | 107.82M | 99.91M | 97.86M | 111.12M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
| Weighted Avg Shares Out (Dil) | 153.96M | 138.03M | 107.82M | 99.91M | 97.86M | 114.47M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022
Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing
CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation
CV Sciences, Inc. (CVSI) Reports Break-Even Earnings for Q3
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q3 2021 Earnings Conference Call - Earnings Call Transcript
Earnings Preview For CV Sciences
CV Sciences, Inc. to Announce Third Quarter 2021 Results on November 15, 2021
CV Sciences, Inc. Applauds the California Legislature for Passage of AB 45
Source: https://incomestatements.info
Category: Stock Reports